

Viatris 2022 Sustainability Report Highlights



Access to medicine is at the core of our mission and begins with sustainably delivering high-quality medicines and health solutions at scale to people, regardless of geography or circumstance.

Viatris is a signatory to the United Nations Global Compact and is committed to the Compact's 10 principles related to human rights, labor, environment and anti-corruption and supports the UN Sustainable Development Goals. <text><text><text><text>

Our Sustainability Goals

These priority areas and initial goals support our sustained operations and our contribution to help advance the global sustainable development goals for 2030, and help us proactively address evolving expectations from stakeholders. To achieve these objectives, diligent work must happen in both the short and the long-term, touching all of us at Viatris.

ACCESS

PROVIDING ACCESS to ARVs

GOAL: Provide antiretroviral (ARV) therapy equivalent to a total of 30 million patients, including more than 2 million children living with HIV/AIDS, between 2022 and the end of 2025.

PROMOTING HCP EDUCATION AND OUTREACH

GOAL: Impact 100 million patients via healthcare professional (HCP) education and outreach regarding prevention, diagnosis and treatment options for noncommunicable diseases (NCDs) including cardiovascular disease, diabetes, cancer and other important chronic conditions to improve outcomes through the NCD Academy by the end of 2025.

DIVERSITY, EQUITY AND INCLUSION

ENGAGING EMPLOYEES ON DEI

GOAL: Engage at least 90% of employees globally on diversity, equity and inclusion (DEI) learning by the end of 2023.

INCREASING DIVERSITY IN MANAGEMENT

GOAL: Increase diversity in management:

- Increase women's representation in senior management globally to at least 35% by the end of 2027.
- At least double Black representation in all management levels in the U.S. by the end of 2027.
- At least double Hispanic/Latinx representation in senior management in the U.S. by the end of 2027.

ENVIRONMENT

PERFORMING WATER RISK ASSESSMENTS

GOAL: Perform water risk assessments for all locations in high or extremely-high water risk areas as identified by the World Resource Institute and identify appropriate water conservation initiatives by 2025.

INCREASING ZERO LANDFILL LOCATIONS

GOAL: Achieve a 50% increase in the number of zero landfill locations by 2030.

©2023 Viatris Inc. All Rights Reserved. VIATRIS and the Viatris Logo are trademarks of Mylan Inc., a Viatris Company. Our sustainability goals are forward-looking targets. Actual results may differ from current projections.

REDUCING GREENHOUSE GAS EMISSIONS

GOAL: Viatris commits to reduce absolute scope 1 and 2 greenhouse gas (GHG) emissions 42% by 2030 from a 2020 base year*. Viatris also commits to reduce absolute scope 3 GHG emissions covering purchased goods and services, capital goods, fuel and energy related activities, and upstream transportation and distribution by 25% within the same timeframe.

*The target boundary includes land-related emissions and removal from bioenergy feedstock.

Building Sustainable Access to Medicine

ACCESS AND GLOBAL HEALTH

At Viatris, we believe that access is incredibly personal. It is fundamental to our mission and a universal need and right, especially important in challenging times.



Sold more than **80 billion** doses of medicine across more than **165 countries and territories**, reaching about **90% of low- and lower middle-income countries** >250 medicines on the WHO Essential Medicines List to help address priority healthcare needs as defined by the WHO

62 products on the WHO Prequalification List, which allows for U.N. and other multilateral donor procurement, as well as accelerated registration processes in low- and lower middle- income countries

OUR PEOPLE

Viatris colleagues are passionate about our mission. Together, we are building a performance-driven, highly engaging and inclusive culture where diverse perspectives drive access, innovation and our ability to make an impact in the world.



We have more than **38,000 colleagues** across almost 70 countries²



89% participation rate in Viatris' first-ever Voice Survey

ENVIRONMENT

Viatris colleagues around the world know that human health and environmental health are closely interconnected. We are committed to doing our part to advance sustainable practices and minimize our environmental footprint while ensuring reliable access to medicine.

The Science Based Target Initiative (SBTi) independently assessed and approved our near-term science-based greenhouse gas emissions reduction targets to cut scope 1 and 2 emissions by 42% by 2030 and scope 3 emissions by 25% by 2030.

COMMUNITY

Giving back to our communities is something our colleagues at Viatris take seriously – and often, personally. Just as global societal issues, the environment and the strength of our workplaces are vital to human health, so too is the wellbeing of our communities. People can truly be empowered to live healthier when their communities are thriving



Donated more than 450 million doses of medicines through our partners around the world

Donated a total of \$1 million to aid

in supporting access to healthcare, food security and water stewardship in communities around the world through four organizations: Direct Relief, World Central Kitchen (WCK), WaterAid and World Food Program USA, the U.S. partner of the United Nations World Food Programme



The Viatris 2022 Sustainability Report also has a management disclosure and performance data section, which includes detailed information about policies, procedures, management systems as well as performance data. Visit viatris.com to learn more.

¹ The number of patients served is an estimate calculated using internal sales data (global volume of doses sold in 2022 in all markets as aligned with IQVIA standard units), divided by estimated per patient usage, which is based on treatment dose, treatment duration, and treatment adherence as estimated by Viatris Medical Affairs based on approved label indication and instructions for use, current international guideline recommendations, and common usage in clinical practice. Patients using multiple Viatris medicines may be counted as multiple patients. Certain adjustments were applied in consideration of announced divestitures and to account for acceptable alternatives to the patient usage factors noted above, and rounded to the nearest hundred million. Estimates may be subject to reassessment.



© 2023 Viatris Inc. All Rights Reserved. VIATRIS and the Viatris Logo are trademarks of Mylan Inc., a Viatris Company.